Derm In-Review welcomes our advertising supporters
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases of the immune system and the central nervous system. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of more than 8,500 employees and operations in 40 countries, we are a global biopharmaceutical company investing nearly 25% of revenue in cutting-edge scientific research to meet unmet patient needs. The company is based in Brussels, Belgium, with U.S. headquarters located in Atlanta, Georgia.